Profil
Mark E.
Gurney was the founder of Tetra Therapeutics Inc. which was founded in 2011, where he held the titles of Chairman & Chief Executive Officer.
He held the position of Director-Genomics Research at Pharmacia Corp.
and Senior Vice President-Drug Discovery & Development at deCODE genetics, Inc. from 2000 to 2010.
Dr. Gurney has an MBA from Northwestern University, a doctorate from California Institute of Technology, and an undergraduate degree from the University of California San Diego.
Anciens postes connus de Mark E. Gurney
| Sociétés | Poste | Fin |
|---|---|---|
Tetra Therapeutics Inc.
 Tetra Therapeutics Inc. BiotechnologyHealth Technology Tetra Therapeutics engages in the development of therapeutic products for neurological disorders. The firm offers BPN14770 PDE4D Inhibitor and PDE4B Inhibitor products. The company was founded by Mark E. Gurney in 2011 and is headquartered in Grand Rapids, MI. | Directeur Général | 30/06/2021 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Corporate Officer/Principal | 22/01/2010 |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Corporate Officer/Principal | - |
Formation de Mark E. Gurney
| University of California San Diego | Undergraduate Degree |
| California Institute of Technology | Doctorate Degree |
| Northwestern University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Tetra Therapeutics Inc.
Tetra Therapeutics Inc. BiotechnologyHealth Technology Tetra Therapeutics engages in the development of therapeutic products for neurological disorders. The firm offers BPN14770 PDE4D Inhibitor and PDE4B Inhibitor products. The company was founded by Mark E. Gurney in 2011 and is headquartered in Grand Rapids, MI. | Health Technology |